Evidence map›Paper›PMID 35930000›Full record

ArticleExpert opinion on drug delivery2022

Localized, on-demand, sustained drug delivery from biopolymer-based materials.

Junqi Wu, Sawnaz Shaidani, Sophia K Theodossiou, Emily J Hartzell, David L Kaplan

Abstract read
In one paragraph

Article in Expert opinion on drug delivery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Recent Advances in the Application of Cucurbitacin B as an Anticancer Agent.International journal of molecular sciences · 2025
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Rapid eradication of vancomycin and methicillin-resistantFrontiers in bioengineering and biotechnology · 2024
    Article
  16. Biopolymers in Drug and Gene Delivery Systems 2.0.International journal of molecular sciences · 2023
    Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Junqi WuDepartment of Biomedical Engineering, Tufts University, Medford, Massachusetts, USA.
Sawnaz ShaidaniDepartment of Biomedical Engineering, Tufts University, Medford, Massachusetts, USA.
Sophia K TheodossiouDepartment of Biomedical Engineering, Tufts University, Medford, Massachusetts, USA.
Emily J HartzellDepartment of Biomedical Engineering, Tufts University, Medford, Massachusetts, USA.
David L KaplanDepartment of Biomedical Engineering, Tufts University, Medford, Massachusetts, USA.

Funding

Tissue Engineering Resource Center: TTDP41EB027062 · NIBIB · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI DAVID L. KAPLAN · 2019 to 2026
$12.6M
Tufts IRACDAK12GM133314 · NIGMS · TUFTS UNIVERSITY BOSTON · PI CLAIRE L MOORE, Jamie Lynn Maguire · 2019 to 2026
$8.4M
Focal Sustained Release Chemotherapy-Loaded Biomaterials at Tumor SitesR01NS094218 · NINDS · TUFTS UNIVERSITY MEDFORD · PI CHIU, BILL, KAPLAN, DAVID L. · 2017 to 2021
$1.7M
NIBIB NIH HHS P41 EB027062NIGMS NIH HHS K12 GM133314NINDS NIH HHS R01 NS094218
6 · The paper itself

Abstract

introductionLocal drug delivery facilitiates higher concentrations of drug molecules at or near the treatment site to enhance treatment efficiency and reduce drug toxicity and other systemic side effects. However, local drug delivery systems face challenges in terms of encapsulation, delivery, and controlled release of therapeutics. AREAS COVERED: We provide an overview of naturally derived biopolymer-based drug delivery systems for localized, sustained, and on-demand treatment. We introduce the advantages and limitations of these systems for drug encapsulation, delivery, and local release, as well as recent applications. EXPERT OPINION: Naturally derived biopolymers like cellulose, silk fibroin, chitosan, alginate, hyaluronic acid, and gelatin are good candidates for localized drug delivery because they are readily chemically modified, biocompatible, biodegradable (with the generation of metabolically compatible degradation products), and can be processed in aqueous and ambient environments to maintain the bioactivity of various therapeutics. The tradeoff between the effective treatment dosage and the response by local healthy tissue should be balanced during the design of these delivery systems. Future directions will be focused on strategies to design tunable and controlled biodegradation rates, as well as to explore commercial utility in substituting biopolymer-based systems for currently utilized synthetic polymers for implants for drug delivery.

Indexed as

Drug Delivery SystemsFibroinsBiocompatible MaterialsBiopolymersHydrogelsPolymersBiocompatible MaterialsBiopolymersFibroinsHydrogelsPolymersbiodegradationBiopolymerhydrogellocalized drug deliverymedical implanton-demand releasesustained release

Identifiers

PMID35930000
PMCPMC9617770

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.